Insider Selling: uniQure (NASDAQ:QURE) Director Sells 1,993 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Jeremy Springhorn sold 1,993 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $53,930.58. Following the completion of the sale, the director directly owned 43,251 shares in the company, valued at approximately $1,170,372.06. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

uniQure Price Performance

QURE traded up $0.75 during trading on Friday, hitting $27.57. The company’s stock had a trading volume of 835,627 shares, compared to its average volume of 2,601,234. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The business’s fifty day simple moving average is $22.31 and its 200 day simple moving average is $21.76. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Analyst Ratings Changes

QURE has been the topic of a number of research analyst reports. Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and lifted their price target for the stock from $11.00 to $35.00 in a research note on Monday, March 9th. The Goldman Sachs Group lifted their price target on uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Monday, April 20th. Wolfe Research initiated coverage on uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp boosted its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares during the last quarter. Arizona State Retirement System boosted its stake in uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after buying an additional 627 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in uniQure by 21.7% during the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after buying an additional 650 shares during the last quarter. Finally, FNY Investment Advisers LLC boosted its stake in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.